Improving adverse drug reaction reporting in hospitals: Results of the french pharmacovigilance in midi-pyrnes region (pharmacomip) network 2-year pilot study

Drug Safety

Volumn 33, Issue 5, 2010, Pages 409-416

  Gony, Mireille ^a   Badie, Kattalin ^a   Sommet, Agns ^a,b   Jacquot, Julien ^a   Baudrin, Dominique ^c   Gauthier, Pierre ^d   Montastruc, Jean Louis ^a,b   Bagheri, Haleh ^a,b  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c Direction Rgionale des Affaires Sanitaires et Sociales ^*  (France)

^d Agence Rgionale DHospitalisation Midi Pyrnes   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIINFECTIVE AGENT; BETA LACTAM DERIVATIVE; BEVACIZUMAB; CLOPIDOGREL; DOXORUBICIN; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; QUINOLONE DERIVATIVE; SULFONAMIDE; SUNITINIB;

ADVERSE DRUG REACTION; ADVERSE OUTCOME; AGED; ANAPHYLACTIC SHOCK; ARTICLE; CAUSE OF DEATH; CONTROLLED STUDY; DRUG FATALITY; DRUG RESEARCH; DRUG SURVEILLANCE PROGRAM; FEMALE; HOSPITAL ADMISSION; HUMAN; LONG TERM CARE; LONGITUDINAL STUDY; MALE; PILOT STUDY; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; SUBARACHNOID HEMORRHAGE;

ADVERSE DRUG REACTION REPORTING SYSTEMS; FRANCE; HOSPITALS, UNIVERSITY; HUMANS; LONGITUDINAL STUDIES; PILOT PROJECTS;

EID: 77951114117     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11319170-000000000-00000     Document Type: Article

References (25)

1. Pouyanne P, Haramburu F, Imbs JL, et al. Admissions to hospital caused by adverse drug reactions: cross sectional incidence study [letter]. French Pharmacovigilance Centres. BMJ 2000; 320: 1036
2. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18820 admissions. BMJ 2004; 329: 15-19 (Pubitemid 38869995)
3. Moore N, Kreft-Jais C, Dhanani A. Spontaneous reporting: France. In: Mann RD, Andrews E, editors. Pharmacovigilance. 2nd ed. Chichester: John Wiley and Sons, Ltd, 2007: 217-226
4. Decret n°95-278 du 13 mars 1995 relatif a la pharmacovigilance et modifiant le code de la sante publique. J Offi-ciel du 14 mars 1995: 3935-3938
5. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356: 1255-1259
6. Figueiras A, Tato F, Fontainas J, et al. Influence of physicians' attitudes on reporting adverse events. Med Care 1999; 37: 809-814
7. Eland IA, Belton KJ, Van Grootheest AC, et al. Attitudinal survey of voluntary reporting of adverse drug reactions. Br J Clin Pharmacol 1999; 48: 623-627 (Pubitemid 29454245)
8. Irujo M, Beitia G, Bes-Rastrollo M, et al. Factors that influence under-reporting of suspected adverse drug reactions among community pharmacists in a Spanish region. Drug Saf 2007; 30: 1073-1082 (Pubitemid 350036605)
9. Herdeiro MT, Figueiras A, Polonia J, et al. Physicians' attitudes and adverse drug reaction reporting: a case-control study in Portugal. Drug Saf 2005; 28: 825-833 (Pubitemid 41428555)
10. Herdeiro MT, Figueiras A, Polonia J, et al. Influence of pharmacists' attitudes on adverse drug reaction reporting: a case-control study in Portugal. Drug Saf 2006; 29: 331-340
11. Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Determinants of under-reporting of adverse drug reactions: a systematic review. Drug Saf 2009; 32: 19-31
12. Bateman DN, Lee A, Rawlins MS, et al. Geographical differences in adverse drug reactions reporting rates in the northern region. Br J Clin Pharmacol 1991; 31: 188-189
13. Sacilotto K, Bagheri H, Lapeyre-Mestre M, et al. Adverse drug effect notifications by nurses and comparison with cases reported by physicians. Therapie 1995; 5: 455-458
14. Begaud B, Evreux JC, Jouglard J, et al. Imputation of the unexpected or toxic effects of drugs: actualization of the method used in France. Therapie 1985; 40: 111-118
15. Burki F, Badie K, Bartoli P, et al. Reversible posterior leukoencephalopathy syndrome associated with bevacizumab/doxorubicin regimen. Br J Clin Pharmacol 2008; 65: 793-794 (Pubitemid 351535098)
16. Pedros C, Vallano A, Cereza G, et al. An intervention to improve spontaneous adverse drug reaction reporting by hospital physicians. Drug Saf 2009; 32: 77-83
17. Herdeiro MT, Polonia J, Gestal-Otero JJ, et al. Improving the reporting of adverse drug reaction: a cluster-rando-mized trial among pharmacists in Portugal. Drug Saf 2008; 31: 335-344 (Pubitemid 351441581)
18. Ekman E, Backstrom M. Attitudes among hospital physicians to the reporting of adverse drug reactions in Sweden. Eur J Clin Pharmacol 2009; 65: 43-46
19. Castel JR, Figueras A, Pedros C, et al. Stimulating adverse drug reaction reporting: effect of a drug safety bulletin and of including yellow cards in prescription pads. Drug Saf 2003; 26: 1049-1055 (Pubitemid 37452645)
20. Feely J, Moriarty S, O'Connor P. Stimulating reporting of adverse drug reaction by using a fee. BMJ 1990; 300: 22-23
21. Backstrom A, Mjorndal T. A small economic inducement to stimulate increased reporting of adverse drug reactions: a way of dealing with an old problem? Eur J Clin Pharma-col 2006; 62: 381-385
22. Backstrom M, Ekman E, Mjorndal T. Adverse drug reaction reporting by nurses in Sweden. Eur J Clin Pharmacol 2007; 63: 613-618
23. Ranganathan SS, Houghton JE, Davies DP, et al. The involvement of nurses in reporting suspected adverse drug reactions: experience with the meningococcal vaccination scheme. Br J Clin Pharmacol 2003; 56: 658-663
24. Morrison-Griffiths S, Walley TJ, Park BK, et al. Reporting of adverse drug reactions by nurses. Lancet 2003; 9366: 1347-1348
25. Ramsay LE. Bridging the gap between clinical pharmacology and rational drug prescribing. Br J Clin Pharmacol 1993; 35: 575-576